Rafael Holdings, Inc.
RFL
Last
$1.60
Day
+8.1%
1y
+11.3%
5y
-95.3%
52w
-62.6%
SPY YTD
+13.3%
XLRE
+1.2%
Earnings
2026-11-0424d
EMA 21
1.77
EMA 50
1.95
EMA 200
1.81
20d high
-36.2%
5y high
-96.0%
5y range
1th
Positions held
Your positionsRFL isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
-16
Hold
avoid
Signal
Strong Sell
Target
$1.80
Stop
$1.21
Stop distance
24.4%
Target vs last
+12.5%
Fundamentals
| Market cap | $76.96M | Enterprise value | $52.49M | Trailing P/E | — | Forward P/E | — |
| PEG | — | Price / book | 1.02 | Beta | 0.34 | Dividend yield | 0.00% |
| Revenue growth | -50.6% | Earnings growth | — | Gross margin | 95.1% | Operating margin | -38.4% |
| Profit margin | 0.0% | ROE | -37.6% | ROA | -22.8% | Debt / equity | 0.01 |
| Current ratio | 3.16 | Free cash flow | -$20.67M | Analyst recommendation | none | Mean target | — |
| 52w high | $3.96 | 52w low | $1.12 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|
| Revenue | $0.2M | $0.2M | $0.2M | $0.4M | $0.1M |
| Op margin | -3838.0% | -3154.0% | -4225.4% | -1633.4% | -4661.0% |
| Net income | -$4.2M | -$6.4M | -$9.8M | -$4.8M | -$4.6M |
| Gross margin | 95.5% | 94.3% | 96.3% | 89.0% | 50.6% |
| Gross profit | $0.2M | $0.2M | $0.2M | $0.3M | $0.0M |
| Operating income | -$6.9M | -$6.7M | -$10.1M | -$5.9M | -$3.6M |
- Revenue -15% vs prior quarter ($0.2M vs $0.2M).
- Gross margin 95.5% (was 94.3% prior quarter).
- Operating margin compressed to -3838%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | — | $0.6M | $0.3M | $0.4M |
| Op margin | — | -16111.0% | -5391.8% | -14750.5% |
| Net income | — | -$34.4M | -$1.9M | -$125M |
| Gross margin | — | 75.8% | 100.0% | — |
| Gross profit | — | $0.5M | $0.3M | — |
| Operating income | — | -$103M | -$15.0M | -$60.5M |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-04 · Rafael’s Trappsol Cyclo Misses Primary Endpoint, Targets 2026 FDA Filing
2026-10-01 · Cyclo goes forth with Niemann-Pick drug’s approval bid despite Phase III miss
2026-09-30 · Rafael Holdings Shares Fall 25% After Trappsol Cyclo Phase 3 Trial Misses Primary Endpoint
2026-09-30 · Rafael Holdings stock tumbles 25% as drug trial misses goal
Price (daily)
Full chart · RSI · MACD · patternsRFL · daily-26.0% over 13 sessions
Close EMA21 EMA50 EMA200
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin